Cargando…
Cenicriviroc, a Novel CCR5 (R5) and CCR2 Antagonist, Shows In Vitro Activity against R5 Tropic HIV-2 Clinical Isolates
BACKGROUND: Maraviroc activity against HIV-2, a virus naturally resistant to different HIV-1 antiretroviral drugs, has been recently demonstrated. The aim of this study was to assess HIV-2 susceptibility to cenicriviroc, a novel, once-daily, dual CCR5 and CCR2 antagonist that has completed Phase 2b...
Autores principales: | Visseaux, Benoit, Charpentier, Charlotte, Collin, Gilles, Bertine, Mélanie, Peytavin, Gilles, Damond, Florence, Matheron, Sophie, Lefebvre, Eric, Brun-Vézinet, Françoise, Descamps, Diane |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4527700/ https://www.ncbi.nlm.nih.gov/pubmed/26247470 http://dx.doi.org/10.1371/journal.pone.0134904 |
Ejemplares similares
-
Pharmacokinetics, Safety, and CCR2/CCR5 Antagonist Activity of Cenicriviroc in Participants With Mild or Moderate Hepatic Impairment
por: Lefebvre, E, et al.
Publicado: (2016) -
Antifibrotic Effects of the Dual CCR2/CCR5 Antagonist Cenicriviroc in Animal Models of Liver and Kidney Fibrosis
por: Lefebvre, Eric, et al.
Publicado: (2016) -
Differential impact of the dual CCR2/CCR5 inhibitor cenicriviroc on migration of monocyte and lymphocyte subsets in acute liver injury
por: Puengel, Tobias, et al.
Publicado: (2017) -
Rationale of using the dual chemokine receptor CCR2/CCR5 inhibitor cenicriviroc for the treatment of COVID-19
por: Files, Daniel Clark, et al.
Publicado: (2022) -
A28 Phylogeographic analysis of HIV-2 ANRS CO5 cohort reveals new trends in HIV-2 epidemic patterns in West Africa
por: Visseaux, B, et al.
Publicado: (2018)